Idiopathic Multicentric Castleman Disease
📧 Sign up to get email alerts when something new happens for Idiopathic Multicentric Castleman Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease [Phase 2]
Phase 2 clinical trial evaluating ruxolitinib in previously treated idiopathic multicentric Castleman disease; recruitment ongoing.
-
EMA approval · 2026-03-24EMA Authorised: Sylvant (siltuximab) — Recordati Netherlands B.V.
The European Medicines Agency has authorized Sylvant (siltuximab) for giant lymph node hyperplasia (Castleman disease) with accelerated asse…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: A Study of Anti-IL-6R mAb Injection in Patients With iMCD [Phase 2]
A Phase 2 study evaluating an anti-IL-6 receptor monoclonal antibody in idiopathic multicentric Castleman's disease is currently active but …
-
CLINICAL_TRIALS trial_result · 2021-02-09Clinical Trial Update: Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial [Phase 2]
A Phase 2 prospective single-arm trial evaluating zanuburutinib for relapsed and refractory idiopathic multicentric Castleman's disease (iMC…
-
CLINICAL_TRIALS trial_result · 2019-06-12Clinical Trial Update: BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) [Phase 2]
Phase 2 clinical trial update for the BCD regimen in newly diagnosed idiopathic multicentric Castleman's disease.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-04-23FDA Approved: SYLVANT — Original Application (Recordati Rare Diseases, Inc.)
The FDA approved Sylvant (siltuximab) under the original application by Recordati Rare Diseases, Inc. for idiopathic multicentric Castleman …